Valuation: BioNTech SE

Market Cap 20.47B 23.35B 18.96B 17.45B 32.91B 2,249B 33.31B 226B 88.56B 1,102B 87.65B 85.76B 3,805B P/E 2026 *
-18.4x
P/E 2027 * -17.7x
Enterprise Value 9.61B 10.97B 8.91B 8.2B 15.46B 1,056B 15.64B 106B 41.59B 518B 41.16B 40.27B 1,787B EV / Sales 2026 *
4.43x
EV / Sales 2027 * 5.01x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+3.25%
Current month-1.34%
1 month+2.40%
3 months-13.73%
6 months-17.00%
Current year-0.12%
1 week 78.9
Extreme 78.9
82.1
1 month 77.8
Extreme 77.8
85.4
Current year 68.65
Extreme 68.65
104
1 year 68.65
Extreme 68.65
104
3 years 68.65
Extreme 68.65
124.5
5 years 68.65
Extreme 68.65
394.1
10 years 65.89
Extreme 65.89
394.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+3.25% - - 23.35B
+1.80%-0.83%+52.79%+86.50% 55.57B
-0.05%+1.23%+56.05%+58.66% 54.26B
+1.50%-1.35%+5.68%+415.28% 23.54B
+0.05%-1.77%+38.71%-4.22% 20.32B
+1.35%-0.74%+35.88%-30.14% 17.36B
+1.08%-3.63%+36.77%+547.87% 15.59B
0.00%-2.08%+165.40%+297.92% 14.96B
+1.06%+0.63%+26.80%+185.02% 14.11B
+2.07%+1.85%+65.22%+153.44% 12.61B
Average +0.86%-1.10%+53.70%+190.04% 25.37B
Weighted average by Cap. +0.83%-1.39%+51.53%+151.99%

Financials

2026 *2027 *
Net sales 2.17B 2.47B 2.01B 1.85B 3.49B 238B 3.53B 23.97B 9.38B 117B 9.28B 9.08B 403B 2.23B 2.55B 2.07B 1.9B 3.59B 245B 3.63B 24.67B 9.65B 120B 9.55B 9.35B 415B
Net income -1.04B -1.19B -966M -889M -1.68B -115B -1.7B -11.53B -4.51B -56.12B -4.46B -4.37B -194B -1.16B -1.33B -1.08B -993M -1.87B -128B -1.9B -12.88B -5.04B -62.72B -4.99B -4.88B -217B
Net Debt -10.85B -12.38B -10.06B -9.26B -17.46B -1,193B -17.67B -120B -46.97B -584B -46.49B -45.49B -2,018B -9.29B -10.59B -8.6B -7.92B -14.93B -1,020B -15.11B -103B -40.18B -500B -39.77B -38.91B -1,726B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-07-19 81.05 +1.00% 0
26-07-21 €81.45 +0.49% 1,240
26-07-20 €81.05 +1.00% 0
26-07-17 €80.25 -0.19% 0
26-07-16 €80.40 +2.10% 388
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.93EUR
Average target price
106.79EUR
Spread / Average Target
+31.96%

Quarterly revenue - Rate of surprise